Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK2 | O43353 | 6/20 | 0.68 |
| ▸ | GAK | O14976 | 6/20 | 0.68 |
| ▸ | COQ8A | Q8NI60 | 5/20 | 0.68 |
| ▸ | NLK | Q9UBE8 | 5/20 | 0.68 |
| ▸ | HTT | P42858 | 1/20 | 0.64 |
| ▸ | EGFR | P00533 | 4/20 | 0.60 |
| ▸ | FADS1 | O60427 | 1/20 | 0.54 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.54 |
| ▸ | HTR2C | P28335 | 1/20 | 0.54 |
| ▸ | HTR2B | P41595 | 1/20 | 0.54 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.51 |
| ▸ | KDR | P35968 | 2/20 | 0.50 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.49 |
| ▸ | DNMT3A | Q9Y6K1 | 1/20 | 0.49 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.49 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.49 |
| ▸ | ABL1 | P00519 | 1/20 | 0.49 |
| ▸ | LCK | P06239 | 1/20 | 0.49 |
| ▸ | SRC | P12931 | 1/20 | 0.49 |
| ▸ | EPHA1 | P21709 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30719618 | 1.00 | RIPK2 (0.68) | RIPK2GAKCOQ8ANLKHTT | |
| SCHEMBL7369676 | 0.83 | HTR2C (0.78) | RIPK2GAKCOQ8ANLKHTR2C | |
| Hydrochloric Acid SCHEMBL7655770 | 0.82 | HTR2C (0.77) | RIPK2GAKCOQ8ANLKHTT | |
| SCHEMBL30307426 | 0.81 | FADS1 (0.60) | RIPK2GAKCOQ8ANLKHTT | |
| SCHEMBL30307392 | 0.81 | EGFR (0.64) | RIPK2GAKCOQ8ANLKHTT | |
| SCHEMBL31197383 | 0.79 | HTT (0.97) | RIPK2GAKCOQ8ANLKHTT | |
| SCHEMBL15923145 | 0.79 | HTT (0.97) | RIPK2GAKCOQ8ANLKHTT | |
| SCHEMBL30307424 | 0.78 | HTT (0.71) | RIPK2GAKCOQ8ANLKHTT | |
| SCHEMBL30880569 | 0.78 | HTT (0.74) | RIPK2GAKCOQ8ANLKHTT | |
| SCHEMBL19283173 | 0.77 | GAK (0.66) | RIPK2GAKCOQ8ANLKHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117586108-A | TOLL-like receptor 8 (TLR 8) specific antagonists, methods of making and uses thereof | 科罗拉多州立大学董事会法人团体 | 2024-02-23 | — | — | CN | claimed |
| CN-117659025-A | TOLL-like receptor 8 (TLR 8) specific antagonists, methods of making and uses thereof | 科罗拉多州立大学董事会法人团体 | 2024-03-08 | — | — | CN | disclosed |
| CN-117586191-A | TOLL-like receptor 8 (TLR 8) specific antagonists, methods of making and uses thereof | 科罗拉多州立大学董事会法人团体 | 2024-02-23 | — | — | CN | disclosed |
| CN-117586108-A | TOLL-like receptor 8 (TLR 8) specific antagonists, methods of making and uses thereof | 科罗拉多州立大学董事会法人团体 | 2024-02-23 | — | — | CN | disclosed |
| CN-111542515-B | TOLL-like receptor 8 (TLR 8) specific antagonists, methods of making and uses thereof | 科罗拉多州立大学董事会法人团体 | 2023-12-05 | — | — | CN | disclosed |
| US-20230132035-A1 | Toll-Like Receptor 8 (TLR8)-Specific Antagonists and Methods of Making and Uses Thereof | UNIV COLORADO REGENTS (US) | 2023-04-27 | — | — | US | disclosed |
| US-11466010-B2 | Toll-like receptor 8 (TLR8) specific antagonists and methods of making and uses thereof | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2022-10-11 | — | — | US | disclosed |
| US-20210179621-A1 | Toll-Like Receptor 8 (TLR8) Specific Antagonists and Methods of Making and Uses Thereof | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE | 2021-06-17 | — | — | US | disclosed |
| CN-111542515-A | TOLL-like receptor 8(TLR8) specific antagonist and preparation method and application thereof | 科罗拉多州立大学董事会法人团体 | 2020-08-14 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230132035-A1 | Toll-Like Receptor 8 (TLR8)-Specific Antagonists and Methods of Making and Uses Thereof | TLR8, TLR3, TLR9 | RIPK2 219/4885GAK 3298/4885COQ8A 404/4885 |
| US-20210179621-A1 | Toll-Like Receptor 8 (TLR8) Specific Antagonists and Methods of Making and Uses Thereof | TLR8, TLR3, TLR9 | RIPK2 184/4885GAK 3469/4885COQ8A 321/4885 |
| US-11466010-B2 | Toll-like receptor 8 (TLR8) specific antagonists and methods of making and uses thereof | TLR8, TLR3, TLR9 | RIPK2 184/4885GAK 3469/4885COQ8A 321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.